Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- Acronyms TIM
- 05 Sep 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2018 Planned End Date changed from 31 Jan 2019 to 31 Jan 2020.